Browse News
Filter News
Found 1,210 articles
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
CAR T-Cell Therapy Market to Rise at a Revenue of US$ 22.2 Billion By 2032
4/23/2024
The global CAR T-Cell Therapy Market is projected to reach USD 22.2 billion by 2032 up from USD 2.1 billion in 2023, at a CAGR of 30% from 2024-2032.
-
T-cell Therapy Market Size, Share & Analysis Report, 2024-2033
4/18/2024
According to Nova One Advisor, the global T-cell therapy market size was valued at USD 3.85 billion in 2023
-
Red Biotechnology Market Size, CAGR, Trends, Report 2024 to 2033
4/18/2024
According to Vision Research Reports, the global red biotechnology market size was estimated at around USD 492.74 billion in 2023
-
Gene Therapy Market Size Poised to Surge USD 52.40 Billion by 2033
4/18/2024
The global gene therapy market size was valued at USD 8.75 billion in 2023 and is poised to grow from USD 10.47 billion in 2024
-
Cancer Gene Therapy Industry is Rising Rapidly Up to USD 18.11 Bn by 2033
4/18/2024
The global cancer gene therapy market size was accounted for USD 2.95 billion in 2023 and it is increasing around USD 18.11 billion by 2033
-
Viral Vector and Plasmid DNA Manufacturing Market Size, CAGR, Share, Report 2024 to 2033
4/16/2024
According to Vision Research Reports, the global viral vector and plasmid DNA manufacturing market size was estimated at around USD 5.37 billion
-
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
4/16/2024
Acumen Pharmaceuticals, Inc. will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver on April 16, 2024.
-
U.S. Gene Therapy Market Size, Share & Growth Report, 2033
4/12/2024
According to Nova One Advisor, the U.S. gene therapy market size was valued at USD 3.19 billion in 2023
-
CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting
4/12/2024
CND Life Sciences today announced that six abstracts related to the identification of phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers in the skin will be presented at the American Academy of Neurology 2024 Annual Meeting (AAN) on April 13-18 in Denver at the Colorado Convention Center.
-
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/11/2024
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to twelve newly hired employees with a grant date of April 9, 2024 (the “Inducement Grants”).
-
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
4/11/2024
Orna Therapeutics today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.
-
A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.
-
Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines
4/9/2024
Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines.
-
U.S. Cell And Gene Therapy Clinical Trial Services industry is Rising Rapidly
4/5/2024
The U.S. cell and gene therapy clinical trial services market size was valued at USD 9.10 billion in 2023 and is anticipated to reach around USD 71.54 billion by 2033, growing at a CAGR of 22.9% from 2024 to 2033.
-
Cell And Gene Therapy Manufacturing Market is Rising Rapidly
4/4/2024
The global cell and gene therapy manufacturing market size was evaluated at USD 9.95 billion in 2023 and is expected to attain around USD 106.03 billion by 2033
-
With several recent approvals in the space and more on the horizon, BioSpace looks at some of the key decisions and their larger significance both for patients and science.
-
Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors
3/28/2024
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
-
While Pfizer has ended one of its two Phase III studies for inclacumab in sickle cell disease, the company is still eyeing an approval for the antibody in the inherited blood disorder by 2026.
-
Vertex and CRISPR Therapeutics are setting up treatment centers for patients with beta thalassemia and sickle cell disease to compete with bluebird’s established infrastructure.